Mauna Kea Technologies (XPAR:ALMKT) Debt-to-EBITDA : (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALMKT Mauna Kea Technologies SA XPAR:ALMKT
39 GF Score
Price €0.15
GF Value €0.14
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Mauna Kea Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mauna Kea Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €0.18 Mil. Mauna Kea Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €11.90 Mil. Mauna Kea Technologies's annualized EBITDA for the quarter that ended in Dec. 2025 was €38.41 Mil. Mauna Kea Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 was 0.31.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Mauna Kea Technologies's Debt-to-EBITDA or its related term are showing as below:

XPAR:ALMKT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -20.38   Med: -1.83   Max: 0.94
Current: 0.94

During the past 13 years, the highest Debt-to-EBITDA Ratio of Mauna Kea Technologies was 0.94. The lowest was -20.38. And the median was -1.83.

XPAR:ALMKT's Debt-to-EBITDA is ranked better than
61.15% of 471 companies
in the Medical Devices & Instruments industry
Industry Median: 1.64 vs XPAR:ALMKT: 0.94

Mauna Kea Technologies  (XPAR:ALMKT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Mauna Kea Technologies Debt-to-EBITDA Related Terms

Mauna Kea Technologies Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Mauna Kea Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mauna Kea Technologies Debt-to-EBITDA Chart

Mauna Kea Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mauna Kea Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

XPAR:ALMKT vs ABT, SYK, MDT: Debt-to-EBITDA Comparison

For the Medical Devices subindustry, Mauna Kea Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mauna Kea Technologies Debt-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Mauna Kea Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mauna Kea Technologies's Debt-to-EBITDA falls into.


XPAR:ALMKT
39GF Score
Mauna Kea Technologies SA XPAR:ALMKT
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mauna Kea Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mauna Kea Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.181 + 11.898) / 15.507
=0.78

Mauna Kea Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.181 + 11.898) / 38.41
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.

Is Mauna Kea Technologies (XPAR:ALMKT) Overvalued in 2026?

Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued. The current stock price of €0.15 is trading 5% above its estimated GF Value™ of €0.14. GuruFocus considers Mauna Kea Technologies to be Fairly Valued.

Key valuation signals for XPAR:ALMKT:

  • Debt-to-EBITDA:
  • GF Value™: €0.14 vs. price of €0.15 (5% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALMKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mauna Kea Technologies Business Description

Other Exchanges 0P5I:UK1MK:Germany
Address 9 rue d\'Enghien, Paris, FRA, 75010
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
39GF Score

Get the complete analysis for XPAR:ALMKT

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.14
GF Value